Literature DB >> 32024728

Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.

Elitza S Theel1, Marisa Sorenson2, Crystal Rahman2, Dane Granger2, Andrew Vaughn3, Laura Breeher3.   

Abstract

Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common condition of employment for health care workers (HCWs) to ensure compliance with national standards and state laws. When documentation of complete vaccination or laboratory-confirmed infection is not available, Advisory Committee on Immunization Practices (ACIP) criteria are used to guide vaccination or anti-MMRV IgG testing. We assessed the performance of the BioPlex 2200 MMRV IgG multiplex flow immunoassay (MFI; Bio-Rad Laboratories, Hercules, CA) and matched immunofluorescence assays (IFAs; MBL Bion, Des Plaines, IL) in 220 HCWs categorized by ACIP criteria for presumptive immunity to MMRV. Among HCWs presumptively immune to measles, mumps, rubella, and VZV, the Bio-Rad MFI was positive in 77.3, 85.4, 84.3, and 91.1% of HCWs, respectively. Comparatively, the Bion IFA was positive in 92.9, 91.1, and 93.5% of HCWs presumptively immune to measles, mumps, and VZV (a rubella IFA was unavailable). Among HCWs fully vaccinated against measles, mumps, and VZV, Bio-Rad MFI/Bion IFA positivity rates were 77.4%/93%, 84.8%/90.7%, and 54.5%/90.9%, respectively. The Bio-Rad MFI was positive in 83.7% of HCWs fully vaccinated against rubella. For HCWs whose last vaccination event occurred within 15 years of enrollment, 83.3, 93.3, and 74.2% were positive by the Bio-Rad measles, mumps, and rubella IgG MFIs, respectively. We show significantly decreased Bio-Rad MFI sensitivity for detection of anti-measles and anti-mumps IgG-class antibodies in presumptively immune or fully vaccinated HCWs. Although negative results typically prompt revaccination, failure to recognize presumptive immunity in individuals unable to receive live, attenuated vaccines may have employment implications.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  MMRV; multiplex immunoflow assay; serology

Mesh:

Substances:

Year:  2020        PMID: 32024728      PMCID: PMC7098756          DOI: 10.1128/JCM.00136-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Authors:  Xin-Xing Gu; Stanley A Plotkin; Kathryn M Edwards; Alessandro Sette; Kingston H G Mills; Ofer Levy; Andrea J Sant; Annie Mo; William Alexander; Kristina T Lu; Christopher E Taylor
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

2.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2011-11-25

Review 4.  Rubella immunity. Defining the level of protective antibody.

Authors:  L P Skendzel
Journal:  Am J Clin Pathol       Date:  1996-08       Impact factor: 2.493

5.  Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.

Authors:  Charles W LeBaron; Judith Beeler; Bradley J Sullivan; Bagher Forghani; Daoling Bi; Carol Beck; Susette Audet; Paul Gargiullo
Journal:  Arch Pediatr Adolesc Med       Date:  2007-03

6.  Immune status of health care workers to measles virus: evaluation of protective titers in four measles IgG EIAs.

Authors:  J Wendelien Dorigo-Zetsma; Maurine A Leverstein-van Hall; Joyce Vreeswijk; Jutte J C de Vries; Ann C T M Vossen; Hinke I Ten Hulscher; Jeroen Kerkhof; Gaby P Smits; Wilhelmina L M Ruijs; Marion P G Koopmans; Robert S van Binnendijk
Journal:  J Clin Virol       Date:  2015-06-24       Impact factor: 3.168

7.  Outbreak of measles among persons with prior evidence of immunity, New York City, 2011.

Authors:  Jennifer B Rosen; Jennifer S Rota; Carole J Hickman; Sun B Sowers; Sara Mercader; Paul A Rota; William J Bellini; Ada J Huang; Margaret K Doll; Jane R Zucker; Christopher M Zimmerman
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

8.  Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Lukas Matter; Susan E Reef; Carol Beck; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

Review 9.  Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella.

Authors:  Judith Breuer; D Scott Schmid; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Bagher Forghani; Carol Beck; Cedric Brown; Daoling Bi; Cynthia Cossen; Bradley J Sullivan
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

View more
  1 in total

1.  Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples.

Authors:  Daniëlle A T Hanssen; Michiel Slaats; Marlies Mulder; Paul H M Savelkoul; Inge H M van Loo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-17       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.